Wake Forest NCORP Research Base
Welcome,         Profile    Billing    Logout  
 12 Trials 
20 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lesser, Glenn J
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
NCT03224767: Vemurafenib and Cobimetinib in Treating Patients with BRAF V600E Mutation Positive Craniopharyngioma

Active, not recruiting
2
24
US
Vemurafenib, Cobimetinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
BRAF V600E Mutation Present, Papillary Craniopharyngioma
10/26
08/28
NCT03532295: Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas

Hourglass Jan 2019 - Jan 2019 : P2 trial in recurrent gliomas
Active, not recruiting
2
51
US
Epacadostat, Bevacizumab, Avastin, Radiation therapy, Peripheral blood draw, Retifanlimab, INCMGA00012
Washington University School of Medicine, Incyte Corporation
Glioma, Glioblastoma
07/24
04/26
WF-1801, NCT03475186: Testing Ramipril to Prevent Memory Loss in People With Glioblastoma

Active, not recruiting
2
75
US, RoW
Ramipril, Altace, Tritace
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Glioblastoma, Radiotherapy; Complications, Cognitive Decline, Chemoradiation
03/25
03/25
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
01/26
01/28
NCT05139056: Multiple Doses of Neural Stem Cell Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas

Recruiting
1
36
US
Neural Stem Cells-expressing CRAd-S-pk7, CRAd-S-pk7 loaded NSCs, NSC-CRAd-S-pk7, NSC-CRAd-S-pk7 Virotherapeutic, NSCs loaded with CRAd-S-pk7, SC-CRAd-Survivin-pk7, Resection, Surgical Resection
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Anaplastic Astrocytoma, Recurrent Anaplastic Oligoastrocytoma, Recurrent Anaplastic Oligodendroglioma, Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Malignant Glioma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma
08/25
08/25
NCT05561374: Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma

Active, not recruiting
1
16
US
Low-dose OKN-007, BID, Low-dose OKN-007, TID, Mid-dose OKN-007, TID, High-dose OKN-007, TID
Oblato, Inc.
High-grade Glioma, Oligodendroglioma, Astrocytoma, Glioblastoma Multiforme
05/25
06/25
TSA, NCT05760079: Lactoferrin for COVID-19-Induced Taste or Smell Abnormality

Withdrawn
N/A
NA
Lactoferrin, Jarrow Formulas Apolactoferrin
Wake Forest University Health Sciences
Covid19, Taste Disorder, Secondary, Taste Disorders, Dysgeusia, Smell Disorder, Ageusia, Anosmia
09/22
09/22
M&M, NCT03998202: Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer

Recruiting
N/A
300
US
Wake Forest University Health Sciences, University of Alabama at Birmingham
Colorectal Cancer, Sarcopenia
12/25
12/25
SHINE, NCT06216574: Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, Trial

Recruiting
N/A
320
US
Internet-based Intervention
Wake Forest University Health Sciences, National Cancer Institute (NCI), University of Virginia
Breast Cancer Female
08/27
08/27
NCT05556447: Internet-delivered Management of Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Recruiting
N/A
26
US
Internet delivered pain coping skills training, PCST
Wake Forest University Health Sciences, HonorHealth Research Institute
CIPN - Chemotherapy-Induced Peripheral Neuropathy
03/25
06/25
TRIDENT, NCT04471844: Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM

Active, not recruiting
N/A
982
Europe, Canada, Japan, US, RoW
Optune®
NovoCure Ltd.
Glioblastoma Multiforme
01/26
01/26
IMPACTS, NCT04462302: An Internet-based Program to Help Cancer Survivors Manage Pain

Recruiting
N/A
456
US, RoW
Internet-based pain coping skills program
Wake Forest University Health Sciences, National Cancer Institute (NCI), National Institute of Neurological Disorders and Stroke (NINDS)
Cancer
10/25
04/26
COSMIC, NCT06418204: Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Recruiting
N/A
2000
US
Non-interventional Study
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Breast Carcinoma, Colorectal Carcinoma, Lung Non-Small Cell Carcinoma, Melanoma, Non-Hodgkin Lymphoma
08/28
08/28
Weaver, Kathryn
NCT05877404: Practice Patterns Among Gynecologic Oncologists on Tumor Genetic Testing in Endometrial Cancer

Terminated
N/A
112
US
Surveys
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Endometrial Cancer
02/24
02/24
NCT05796518: Feasibility of a Patient Directed Tool to Assess Heart Health Among Endometrial Cancer Survivors

Completed
N/A
42
US
PREVENT Cardiovascular Health Assessment Tool, Survey, Interview Regarding Heart Health
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Endometrial Cancer, Survivorship
06/24
06/24
AH-HA, NCT03935282: Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors

Active, not recruiting
N/A
645
US
AH-HA Tool in the EPIC EHR
Wake Forest University Health Sciences, National Cancer Institute (NCI), Washington University School of Medicine, University of Texas Southwestern Medical Center
Breast Neoplasm, Prostatic Neoplasm, Colorectal Neoplasms, Endometrial Neoplasms, Hodgkin Disease, Non Hodgkin Lymphoma
03/25
03/25
HRSN, NCT06412029: Understanding and Enhancing Health-Related Social Needs () Screening Among Community Oncology Practices

Enrolling by invitation
N/A
144
US
Non-Interventional
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Cancer
08/26
11/26
CONNECT, NCT06383988: A Web-based Program to Help Caregivers of Lung Patients Learn About Available Supportive Care Resources

Enrolling by invitation
N/A
240
US
Support for Caregiver - Generic List, Support for Caregiver - Personalized List, Internet-Based Intervention - CONNECT, Patient Navigation, Patient Navigator Program
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Stage II Lung Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
10/25
01/26
NCT04395495: RASopathy Biorepository

Recruiting
N/A
1000
US
Children's Hospital Medical Center, Cincinnati
RAS Mutation, Neurofibromatosis 1, Noonan Syndrome, Noonan Syndrome With Multiple Lentigines, Noonan Neurofibromatosis Syndrome, Cardiofaciocutaneous Syndrome, Costello Syndrome, Legius Syndrome, Smith-Kingsmore Syndrome, MTOR Gene Mutation, GATOR-1 Gene Mutation, SYNGAP1-Related Intellectual Disability, DLG4, MAPK1 Gene Mutation
12/65
12/65

Download Options